Plain-English translation of NCT07445048 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new treatment plan for people with advanced head and neck squamous cell carcinoma (a type of cancer) who have already had surgery and cannot tolerate standard chemotherapy. The plan combines radiation therapy with a medication called , followed by another medication called Benmelstobart. Researchers want to see if this approach can help prevent the cancer from returning and improve survival.
Many patients with advanced head and neck cancer are too frail, too old, or have kidney or hearing problems that make standard chemotherapy too risky. This trial exists to find a safer, effective treatment option for these patients who need additional treatment after surgery but cannot receive traditional chemotherapy.
You likely qualify if…
You likely don't qualify if…
Participants will receive radiation therapy combined with the medication over several weeks, followed by treatment with the medication Benmelstobart. The trial expects to last about 5 years total—roughly 2 years for enrollment and treatment, then 3 years of follow-up visits where doctors monitor your health and check whether the cancer has returned. You will have regular clinic visits, blood tests, and imaging scans to track how you are doing.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China